Quintiles continues seeking more small biopharma with new solution

14-Sep-2014 - Last updated on 15-Sep-2014 at 08:03 GMT

The tool leverages Quintiles’ integrated technology platforms to provide customers with real-time data access as well as a transparent view of project performance.

Related tags Customer Customer service

Recognizing the critical role of emerging biopharma companies and their recent influx of cash, Quintiles has launched a new ‘emerging biopharma solution’ that aims to capitalize on the unique development needs of the companies.

The tool, known as the Quintiles Emerging Biopharma Solution, is an operating model that leverages Quintiles’ integrated technology platforms to provide customers with real-time data access as well as a transparent view of project performance. In addition to providing a dedicated leader with emerging biopharmaceutical operations expertise, the offering includes senior-level sponsorship for each customer. This level of support provides easy access to the unique expertise and nimble operational support required by these companies.

“Small and emerging biopharmaceutical companies have been an important customer segment for Quintiles for the past 30+ years of our company’s existence. Over the past five years, we have worked with 240 emerging biopharmaceutical customers. More recently, we’ve seen a marked increase in the demand from this customer segment. In fact, Quintiles grew its net new business from emerging biopharmaceutical customers by two and a half times in the first six months of 2014 compared to the same period in 2013,” Josh Rose of Quintiles’ Enterprise Solutions Development team told Outsourcing-pharma.com.

“We designed this solution to focus squarely on the challenges that emerging biopharma customers face by combining an operational model with dedicated support with access to Quintiles’ global infrastructure, integrated technology and therapeutic expertise,” he added.

The new offering covers all therapeutic areas and adds to the proven oncology expertise of Novella Clinical, which Quintiles acquired a little more than a year ago.

Quintiles’ work with small biopharma has centered on their specific needs in areas such as study start-up, patient recruitment and trial execution, which are all part of this new offering.

Rose noted that this solution was designed to provide emerging biopharma customers with clinical development expertise in a “nimble and focused operating model designed with their unique needs in mind.” This new offering includes:

Dedicated project leadership with experience serving this customer segment;
Executive governance;
Quintiles’ global reach and partnerships;
A new operating model to meet the specific requirements for emerging biopharmaceutical customers;
Access to Quintiles’ various data systems for timely, transparent views into project performance and up-to-date analytics to help guide decisions;
PM’s dedicated to serving emerging biopharma customers;
Quintiles-driven start up, including best practices and site selection; and
Quintiles processes and SOPs.

“Through our experience working with emerging biopharma customers, we understand they typically have leaner organizations with an affinity for fast decision making. They want access to world class development capabilities while working in a collaborative environment,” Rose added.